About Us
Therapeutic Systems Research Laboratories (TSRL), Inc. is a privately owned preclinical accelerator based in Ann Arbor, Michigan. Our 7,200 sq. ft. facility has 5,000 sq. ft. of wet lab space, and includes: analytical chemistry, formulation, cell culture, and in vivo testing.
Our Approach
We build on our success co-developing technologies through academic partnerships by providing infrastructure, expertise, and an avenue to non-dilutive funding. In an effort to advance our lead candidates into clinical development, we have developed an asset-centric portfolio built on promising lead-stage anti-infective compounds.
Below are academic, government, and industry organizations who have worked with us to develop better medicines for underserved populations.
Recent News and Events
TSRL, Inc. today announced its contribution to a newly published study in Microbiology Spectrum by the American Society of Microbiology (ASM) evaluating the in vitro activity of MRS-2541, a novel methionyl-tRNA synthetase inhibitor designed to target serious gram-positive hospital infections.
The Michigan Mass Spectrometry Discussion Group Symposium, held March 18, 2026 at the Van Andel Institute in Grand Rapids, brought together experts across academia and industry to discuss advances, challenges, and future directions in mass spectrometry. TSRL’s John Takyi-Williams, PhD, Senior Research and Project Scientist, Analytical, attended and shared key observations.
TSRL, Inc. President and CEO Dr. Elke Lipka and Senior Advisor Dr. Jessica Reed have been named to Purpose Jobs’ “43 Top Women in Tech to Know in 2026” list, recognizing leaders who are driving meaningful innovation across technology and science.
